Nektar Therapeutics today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking oral abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback